Dasatinib in Treating Patients With Chronic Lymphocytic Leukemia

Inclusion Criteria

• Written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization for release of personal information
• Eastern Cooperative Oncology Group (ECOG) = = 65 who are not candidates for or do not want to pursue aggressive chemotherapy treatment
• Have indications for treatment or evidence of progressive disease defined as follows (1996 NCI working group):
• Massive or progressive splenomegaly
• Massive lymph nodes (>= 10 cm), nodal clusters (>= 10 cm), or progressive lymphadenopathy
• Symptomatic anemia and/or thrombocytopenia (Rai stages III or IV disease)
• Autoimmune hemolytic anemia and/or thrombocytopenia that are poorly responsive to corticosteroid therapy
• Progressive lymphocytosis with increase in lymphocyte count of >= 50% over a 2-month period or an anticipated doubling time of 30,000
• Ability to take oral medication (dasatinib must be swallowed whole)
• No clinically significant infections as determined by the investigator
• Normal corrected QT (QTc) interval ( = 50,000/mm^3

Exclusion Criteria

• Patients may not receive concurrent chemotherapy, radiotherapy, or immunotherapy
• Pleural or pericardial effusion of any grade
• Uncontrolled angina, > New York Heart Association (NYHA) class III congestive heart failure or myocardial infarction (MI) within 6 months prior to study enrollment
• Diagnosed congenital long QT syndrome
• Any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or Torsades de pointes)
• Prolonged QTc interval on pre-entry electrocardiogram (> 450 msec)
• Subjects who are detained or imprisoned are not eligible
• History of significant bleeding disorder unrelated to cancer, including:
• Diagnosed congenital bleeding disorders (e.g., von Willebrand's disease)
• Diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies)
• May not take concomitant medications that are generally accepted to have a risk of causing Torsades de Pointes including: (patients must discontinue drug 7 days prior to starting dasatinib)
• Quinidine, procainamide, disopyramide
• Amiodarone, sotalol, ibutilide, dofetilide
• Erythromycin, clarithromycin
• Chlorpromazine, haloperidol, mesoridazine, thioridazine, pimozide
• Cisapride, bepridil, droperidol, methadone, arsenic, chloroquine, domperidone, halofantrine, levomethadyl, sparfloxacin, lidoflazine
• Patients already taking other CYP inducers or inhibitors other than those listed above are eligible for the study only after principal investigator (PI) review; dose adjustments and/or monitoring of drug levels where applicable will be made as needed by the PI after consultation with pharmacy
• Women who:
• Are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for at least 4 weeks after cessation of study drug, or
• Have a positive pregnancy test at baseline, or
• Are pregnant or breastfeeding